Binding Arbitration Proposed As Fix To Expensive Rx Prices In Part D

Congress could allow for binding arbitration to help plans negotiate lower prices for unique specialty drugs, Harvard professors wrote in a January 2008 Health Affairs article that is getting new attention in light of the $94,500 price of a 12-week course of the newly approved hepatitis C drug Harvoni. The Center for a Responsible Federal Budget drew attention to the old proposal to help advance the debate over how, or whether, steps should be taken to control the price...